Product List


Effient®,co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).

show more


Humalog® insulins are insulin lispro, which works more quickly than soluble human insulin because the insulin molecule has been changed slightly.

Humalog Mix25® is 25% insulin lispro and 75% insulin lispro protamine suspension.

Humalog Mix50® is 50% insulin lispro and 50% insulin lispro protamine suspension.

show more

Humulin®is used to reduce high blood sugar (glucose) levels in patients with diabetes mellitus, both type 1 and type 2 diabetes requiring insulin.

Humulin®(Insulin Biosynthetic) is found to chemically, physically, biologically and immunologically equivalent to pancreatic human insulin which differs slightly from porcine or bovine insulin in amino acid composition.

show more


Cialis®, treatment of erectile dysfunction.

show more


TERIPARATIDE (rDNA) Forteo®, is indicated in adults. It is for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture
Reference: Forteo prescribing information: PA005FSHK02

show more


ATOMOXETINE HYDROCHLORIDE Strattera®, a selective norepinephrine reuptake inhibitor intended for oral administration only. It is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents and adults.

show more

DULOXETINE HYDROCHLORIDE Cymbalta®,is indicated for the treatment of major depressive disorder,diabetic neuropathic pain and generalized anxiety disorder.

show more

Zyprexa Zydis® , Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and other psychoses where positive symptoms (e.g., delusions, hallucinations, disordered thinking, hostility, and suspiciousness) and/or negative symptoms (e.g., flattened affect, emotional and social withdrawal, poverty of speech) are prominent. Olanzapine also alleviates the secondary affective symptoms commonly associated with schizophrenia and related disorders.

Olanzapine is effective in maintaining the clinical improvement during continuing therapy in patients who have shown initial treatment response.

Olanzapine as monotherapy or in combination with lithium or valproate is indicated for the treatment of acute manic or mixed episodes in bipolar disorder with or without psychotic features and with or without a rapid cycling course.

Olanzapine is indicated for the prevention of recurrence in patients with bipolar mania.

show more


Build a treatment strategy for survival with ALIMTA®. Discover why ALIMTA is the foundational therapy for thoracic cancers. Learn more about ALIMTA/cisplatin for the treatment of first line advanced NSCLC with nonsquamous* cell histology.
*Adenocarcinoma, large cell carcinoma, and other histologies.

show more

Gemzar® Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.
Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy.
Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.

show more